Post-Acute Cardiovascular Outcomes of COVID-19 in Children and Adolescents: An EHR Cohort Study from the RECOVER Project

3

4 Author list

Bingyu Zhang, MS^{1,2}, Deepika Thacker, MD³, Ting Zhou, MD, PhD^{1,4}, Dazheng Zhang, MS^{1,4},
Yuqing Lei, MS^{1,4}, Jiajie Chen, PhD^{1,4}, Elizabeth Chrischilles, PhD⁵, Dimitri A. Christakis, MD,
MPH⁶, Soledad Fernandez, PhD⁷, Vidu Garg, MD^{8,9}, Susan Kim, MD, MMSc¹⁰, Abu S. M.
Mosa, PhD, MS, FAMIA¹¹, Marion R. Sills, MD, MPH^{12,13}, Bradley W. Taylor, MBA, FAMIA¹⁴,
David A. Williams, PhD¹⁵, Qiong Wu, PhD^{1,4}, Christopher B. Forrest, MD, PhD^{16*}, and Yong
Chen, PhD^{1,2,4,17,18,19*} on behalf of the RECOVER Initiative

11

12 Affiliations

- 13 1. The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania,
- 14 Philadelphia, PA, USA
- 15 2. The Graduate Group in Applied Mathematics and Computational Science, School of Arts and
- 16 Sciences, University of Pennsylvania, Philadelphia, PA, USA
- 17 3. Nemours Cardiac Center, Nemours Children's Health System, Wilmington, DE, USA
- 18 4. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania
- 19 Perelman School of Medicine, Philadelphia, PA, USA
- 20 5. Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City,
- 21 IA, USA
- 6. Center for Child Health, Behavior and Development, Seattle Children's Research Institute,Seattle, WA, USA
- 7. Department of Biomedical Informatics and Center for Biostatistics, Ohio State University,Columbus, OH, USA
- 26 8. Heart Center and Center for Cardiovascular Research, Nationwide Children's Hospital,
- 27 Columbus, OH, USA
- 28 9. Department of Pediatrics, The Ohio State University, Columbus, OH, USA
- 29 10. Division of Pediatric Rheumatology, Benioff Children's Hospital, University of California
- 30 San Francisco, San Francisco, CA, USA
- 31 11. Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University
- 32 of Missouri School of Medicine, Columbia, MO, USA
- 33 12. Department of Research, OCHIN, Inc., Portland, OR, USA
- 34 13. Department of Pediatrics, University of Colorado School of Medicine and Children's
- 35 Hospital Colorado, Aurora, CO, USA
- 36 14. Clinical and Translational Science Institute, Medical College of Wisconsin, Milwaukee, WI,
- 37 USA

- 38 15. Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA
- 39 16. Applied Clinical Research Center, Department of Pediatrics, Children's Hospital of
- 40 Philadelphia, Philadelphia, PA, USA
- 41 17. Leonard Davis Institute of Health Economics, Philadelphia, PA, USA
- 42 18. Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA
- 43 19. Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA
- 44

45 *: Senior authors

46 47	Corresponding authors:	Yong Chen, Ph.D. University of Pennsylvania
48		Blockley Hall 602, 423 Guardian Drive
49		Philadelphia, PA 19104
50		Office: 215-746-8155
51		E-mail: <u>ychen123@pennmedicine.upenn.edu</u>
52		
53		Christopher B. Forrest, MD, Ph.D.
54		Applied Clinical Research Center
55		Department of Pediatrics, Children's Hospital of Philadelphia
56		Philadelphia, PA 19104
57		E-mail: <u>forrestc@chop.edu</u>

58

59 Authorship Statement

- 60 Authorship has been determined according to ICMJE recommendations.
- 61

62 Word Count (does not include the title page, abstract, references, tables, and figure legends):

- **63** 3158
- 64

65 Total Word Count (including Title Page, Abstract, Text, References, Tables and Figures66 Legends):

68 Abstract

69 Background The risk of cardiovascular outcomes in the post-acute phase of SARS-CoV-2 70 infection has been quantified among adults and children. This paper aimed to assess a multitude 71 of cardiac signs, symptoms, and conditions, as well as focused on patients with and without 72 congenital heart defects (CHDs), to provide a more comprehensive assessment of the post-acute 73 cardiovascular outcomes among children and adolescents after COVID-19.

Methods This retrospective cohort study used data from the RECOVER consortium comprising 19 US children's hospitals and health institutions between March 2020 and September 2023. Every participant had at least a six-month follow-up after cohort entry. Absolute risks of incident post-acute COVID-19 sequelae were reported. Relative risks (RRs) were calculated by contrasting COVID-19-positive with COVID-19-negative groups using a Poisson regression model, adjusting for demographic, clinical, and healthcare utilization factors through propensity scoring stratification.

81 **Results** A total of 1,213,322 individuals under 21 years old (mean[SD] age, 7.75[6.11] years; 82 623,806 male [51.4%]) were included. The absolute rate of any post-acute cardiovascular 83 outcome in this study was 2.32% in COVID-19 positive and 1.38% in negative groups. Patients 84 with CHD post-SARS-CoV-2 infection showed increased risks of any cardiovascular outcome 85 (RR, 1.63; 95% confidence interval (CI), 1.47-1.80), including increased risks of 11 of 18 post-86 acute sequelae in hypertension, arrhythmias (atrial fibrillation and ventricular arrhythmias), 87 myocarditis, other cardiac disorders (heart failure, cardiomyopathy, and cardiac arrest), thrombotic disorders (thrombophlebitis and thromboembolism), and cardiovascular-related 88 89 symptoms (chest pain and palpitations). Those without CHDs also experienced heightened cardiovascular risks after SARS-CoV-2 infection (RR, 1.63; 95% CI, 1.57-1.69), covering 14 of
18 conditions in hypertension, arrhythmias (ventricular arrhythmias and premature atrial or
ventricular contractions), inflammatory heart disease (pericarditis and myocarditis), other
cardiac disorders (heart failure, cardiomyopathy, cardiac arrest, and cardiogenic shock),
thrombotic disorders (pulmonary embolism and thromboembolism), and cardiovascular-related
symptoms (chest pain, palpitations, and syncope).

96 Conclusions Both children with and without CHDs showed increased risks for a variety of
97 cardiovascular outcomes after SARS-CoV-2 infection, underscoring the need for targeted
98 monitoring and management in the post-acute phase.

99 Clinical Perspective section

100 What is new?

101	٠	We investigated the risks of 18 post-acute COVID-19 cardiovascular outcomes in the
102		pediatric population without Multisystem Inflammatory Syndrome in Children (MIS-C)
103		in over 1 million patients, stratified by congenital heart defects (CHD) status.
104	•	We extended the follow-up period beyond previous pediatric studies, ensuring every
105		participant had at least a six-month follow-up after cohort entry.
106	•	We included a comprehensive cross-section of the US pediatric population across various
107		healthcare settings including primary, specialty, and emergency care, as well as testing
108		and inpatient facilities.
109	What a	are the clinical implications?
110	•	Within the post-acute phase, children and adolescents previously infected with SARS-
111		CoV-2 are at statistically significant increased risk of incident cardiovascular outcomes,
112		including hypertension, ventricular arrhythmias, myocarditis, heart failure,
113		cardiomyopathy, cardiac arrest, thromboembolism, chest pain, and palpitations. These
114		findings are consistent among patients with and without CHDs.
115	•	Awareness of the heightened risk of cardiovascular disorders after COVID-19 can lead to
116		a timely referral, investigations, and management of these conditions in children and
		adolescents

118 Introduction

Recent research has highlighted the post-acute sequelae of SARS-CoV-2 (PASC), or "long
COVID", which appears after the initial four weeks of acute infection.¹ This condition
encompasses a spectrum of symptoms affecting multiple organ systems, including cardiovascular
outcomes.^{2,3} A few studies have reported increased long-term cardiovascular effects of COVID19 in adults.⁴⁻¹¹

124 Compared to adults, the incidence of long COVID is low in the pediatric population, including conditions such as myocarditis and general cardiorespiratory signs and symptoms.^{3,12} However, 125 126 increased cardiovascular complications post-COVID-19 in the pediatric population were found 127 in several studies, though these were limited by short follow-up periods and focused mainly on 128 specific outcomes like myocarditis, pericarditis, and multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C).¹³⁻¹⁶ In adults, those with pre-existing 129 130 cardiovascular risk factors or established cardiovascular disease face a higher risk of severe COVID-19 and cardiovascular PASC.^{17,18} In children and adolescents, congenital heart disease 131 (CHD) constitutes the most common congenital disorder¹⁹, but its effect on the risk of 132 133 developing cardiovascular PASC has not been reported.

Our study utilizes data from the Researching COVID to Enhance Recovery (RECOVER) electronic health records (EHR) system to conduct a thorough evaluation of cardiovascular signs, symptoms, and conditions in children and adolescents with and without CHDs, to understand the post-acute cardiovascular impacts of COVID-19. This study has several strengths. First, this is the first and largest study to provide a comprehensive analysis of post-acute cardiovascular COVID-19 sequelae in the pediatric population. Second, the study extended the follow-up period beyond previous pediatric studies. Third, the study included a comprehensive cross-section of the US pediatric population across various healthcare settings including primary, specialty, and emergency care, as well as testing and inpatient facilities. Finally, our analysis incorporates CHDs as a key variable to enhance the precision of our findings, recognizing its prevalence as the most common congenital disorder in pediatrics.

145 Methods

146 Data Sources and Cohort Construction

This study is part of the National Institutes of Health (NIH) funded RECOVER Initiative (<u>https://recovercovid.org/</u>), which aims to learn about the long-term effects of COVID-19. This study included nineteen US children's hospitals and health institutions. The EHR data was standardized to the PCORnet Common Data Model (CDM) and extracted from the RECOVER Database Version s10. More details are available in the Supplementary Materials.

We conducted a retrospective study from March 1, 2020, to September 1, 2023, with a cohort entry period extending from March 1, 2020, to March 6, 2023, ensuring at least a 179-day follow-up for observing post-acute COVID-19 outcomes. We included patients under 21, who had at least one healthcare visit within the baseline period, defined as 24 months to 7 days before the index date, and at least one encounter within the follow-up period, defined as 28 to 179 days after the index date.

In our study, documented SARS-CoV-2 infections were defined by positive polymerase-chainreaction (PCR), serology, antigen tests, or diagnoses of COVID-19, or diagnoses of PASC. For the comparator group, we required all tests to be negative, no evidence or diagnosis of COVID-161 19 or PASC during the study period, and at least one negative COVID-19 test within the cohort 162 entry period. The index date for COVID-19 patients was set as either the earliest date of positive 163 tests, COVID-19 diagnoses, or 28 days before a PASC diagnosis. For COVID-19-negative 164 patients, the index date was a randomly selected date from their negative tests to align the 165 distribution of index dates between the two groups, controlling for time effects.

Patients diagnosed with MIS-C, Kawasaki disease, chronic kidney disease (CKD), or end-stage
kidney disease (ESKD) were excluded.^{20–25} Although MIS-C is considered a PASC, it was not
included in this study's post-acute cardiovascular outcomes for two reasons: children with MISC can be effectively treated with minimal post-acute cardiac sequelae,²⁶ and MIS-C has been and
continues to be extensively studied with significantly declining incidence over the past year.²⁷
Figure 1 summarizes the participant selection for both COVID-19 positive and negative groups.

172 Defining Cardiovascular Outcomes

173 We identified 18 post-acute cardiovascular outcomes for our study, including hypertension, atrial 174 fibrillation, ventricular arrhythmias, atrial flutter, premature atrial or ventricular contractions, 175 pericarditis, myocarditis, heart failure, cardiomyopathy, cardiac arrest, cardiogenic shock, 176 pulmonary embolism, deep vein thrombosis, thrombophlebitis, thromboembolism, chest pain, palpitations, and syncope. These outcomes were assessed during the follow-up period in patients 177 178 without a history of the specific condition during the baseline period. We used validated 179 diagnostic codes (ICD10CM, ICD10, ICD9CM, SNOMED) confirmed by two board-certified 180 pediatricians (DT, CF), with details of the code sets available in the Supplementary Materials.

We also grouped related cardiovascular outcomes into categories, including arrhythmias (atrial
fibrillation, ventricular arrhythmias, atrial flutter, and premature atrial or ventricular
contractions), inflammatory heart disease (pericarditis and myocarditis), other cardiac disorders

(heart failure, cardiomyopathy, cardiac arrest, and cardiogenic shock), thrombotic disorders
(pulmonary embolism, deep vein thrombosis, thrombophlebitis, and thromboembolism),
cardiovascular-related symptoms (chest pain, palpitations, and syncope), and any cardiovascular
outcome (any incident cardiovascular condition studied).

188 Covariates

189 We examined a comprehensive set of patient characteristics as measured confounders collected before cohort entry, to be adjusted through propensity score stratification²⁸ to balance the 190 191 comparison groups. These included demographic factors, including age at index date, gender (female, male), and race/ethnicity (Non-Hispanic White (NHW), Non-Hispanic Black (NHB), 192 193 Hispanic, Asian American/Pacific Islander (AAPI), Multiple, Other/Unknown); clinical factors, 194 including obesity status, a chronic condition indicator defined by the Pediatric Medical Complexity Algorithm²⁹ (PMCA, no chronic condition, non-complex chronic condition, complex 195 chronic condition), and a list of pre-existing chronic conditions^{3,30}; health care utilization factors 196 197 collected 24 months to 7 days before index date, including the number of inpatient visits, 198 outpatient visits, emergency department (ED) visits, unique medications, and negative COVID-19 tests (0, 1, 2, \geq 3); vaccine information, including dosage of COVID-19 vaccine before index 199 date (0, 1, \geq 2) and interval since the last COVID-19 immunization (no vaccine, <4 months, \geq 4 200 201 months); year-month of cohort entry (from March 2020 to March 2023); indicators from the 19 202 data-contributing sites.

203 Statistical Analysis

We calculated the incidence of post-acute cardiovascular outcomes in COVID-19-positive and negative cohorts, stratified by CHD status. For each outcome, incidence rates were calculated by 206 dividing new cases during the follow-up period by the total number of patients, excluding those207 with the specific outcome at baseline.

208 We presented distributions of preference scores—a transformation of propensity scores 209 accounting for prevalence differences between populations—to assess empirical equipoise³¹. 210 Empirical equipoise is achieved for COVID-19 positive and negative patients when the majority of individuals in both groups have preference scores ranging from 0.3 to 0.7.^{28,31} To mitigate the 211 effects of confounding, we used propensity score stratification²⁸ to adjust for a large number of 212 measured confounders collected before index date. After stratification, we assessed the 213 standardized mean difference (SMD) of each covariate between COVID-19 positive and 214 negative patients, with an SMD of 0.1 or less indicating acceptable balance.^{28,32} 215

We used the stratified Poisson regression model to estimate the relative risk (RR) for each outcome between comparison groups for patients with and without CHD. RR is a collapsible measure, meaning the measure of association conditional on some factors remains consistent with the marginal measure collapsed over strata, which is crucial for accurate interpretation in clinical research.^{33,34}

We also conducted subgroup analyses by age (0-4, 5-11, 12-20 years), race/ethnicity (NHW, NHB, Hispanic), gender (male and female), obesity status (obese and non-obese), severity of acute COVID-19³⁵ ("non-severe" including asymptomatic and mild, "severe" including moderate and severe), and estimated time frames corresponding to dominant virus variants (pre-Delta, Delta, Omicron). Specifically, the pre-Delta variant spanned March 1, 2021, to June 30, 2021; Delta from July 1, 2021, to December 31, 2021; and Omicron from January 1, 2022, to March 6, 2023, with a minimum 179-day follow-up to observe long COVID outcomes.³⁶

228 Sensitivity Analysis

229 We conducted extensive sensitivity analyses to examine the robustness of our findings. Negative control outcome experiments^{28,37,38} were performed to calibrate the residual study bias from 230 231 unmeasured confounders and systematic sources, in which the null hypothesis of no effect was 232 believed to be true utilizing a list of 36 negative control outcomes determined by two board-233 certified pediatricians (DT, CF). The empirical null distribution and calibrated risks were 234 reported in Supplementary Materials Section S3. Additional analyses were performed excluding 235 patients included solely based on a PASC diagnosis (Section S4) and those without any 236 cardiovascular outcomes within the baseline period (Section S5). Given limited SARS-CoV-2 237 testing availability during the first wave of COVID-19 (March to May 2020), we conducted 238 analyses excluding patients whose index dates fell within this period (Section S6). Furthermore, 239 we excluded data from site L where the population is truncated at the ambulatory level (Section 240 **S7**). All analyses were performed using R version 4.0.2.

241 **Results**

242 Cohort Identification

A total of 297,920 children and adolescents with COVID-19 (24.6%; 13,646 with CHDs, 284,274 without) and 915,402 without COVID-19 (75.4%; 46,962 with CHDs, 868,440 without) in the RECOVER Database were included. Among these patients, 623,806 (51.4%) were male with a mean (SD) age of 7.75 (6.11) years. Baseline characteristics by COVID-19 and CHD status are detailed in **Table 1**.

248 Incidence of Post-acute Cardiovascular Events

249 Table 2 presents the incidence of 18 individual and 6 composite post-acute cardiovascular 250 outcomes for COVID-19-positive compared to COVID-19-negative patients, stratified by CHD 251 status. The data indicate that COVID-19-positive patients generally have higher incidences in 252 both CHD and non-CHD groups. For example, the absolute risk of heart failure was 1.61% in 253 COVID-19-positive patients with CHD, compared to 1.18% in their COVID-19-negative 254 counterparts. Similarly, chest pain incidence was 1.23% in COVID-19-positive patients without 255 CHD, versus 0.61% in COVID-19-negative patients. Overall, the CHD group showed higher 256 absolute risks of any post-acute cardiovascular outcomes than the non-CHD group, with 5.57% 257 for positive and 4.00% for negative patients with CHD, compared to 2.19% and 1.26% 258 respectively in those without CHD.

259 Adjusted Relative Risk of post-acute Cardiovascular Outcomes

The COVID-19 positive and negative patients achieved empirical equipoise (**Figure S2**), with well-balanced characteristics after propensity score stratification (**Figure S3**). **Figure 2** highlights that post-acute cardiovascular outcomes are higher in both CHD and non-CHD groups among patients with COVID-19 compared to negative ones.

Composite outcomes demonstrated increased risks in both groups. For CHD patients, there were
increases across any cardiovascular outcome (RR, 1.63; 95% CI, 1.47-1.80), arrhythmias (RR,
1.52; 95% CI, 1.22-1.89), other cardiac disorders (RR, 1.69; 95% CI, 1.46-1.96), thrombotic
disorders (RR, 1.42; 95% CI, 1.13-1.78), and cardiovascular-related symptoms (RR, 1.95; 95%
CI, 1.66-2.31). For non-CHD patients, increases were noted in any cardiovascular outcome (RR,
1.63; 95% CI, 1.57-1.69), arrhythmias (RR, 1.47; 95% CI, 1.24-1.75), inflammatory heart
disease (RR, 2.92; 95% CI, 2.25-3.78), other cardiac disorders (RR, 1.50; 95% CI, 1.26-1.78),

thrombotic disorders (RR, 1.26; 95% CI, 1.09-1.45), and cardiovascular-related symptoms (RR,
1.68; 95% CI, 1.62-1.75).

273 Individual outcomes also showed increased risks. CHD patients experienced higher risks in 274 hypertension (RR, 1.58; 95% CI, 1.32-1.89), atrial fibrillation (RR, 2.64; 95% CI, 1.15-6.05), 275 ventricular arrhythmias (RR, 1.50; 95% CI, 1.18-1.89), myocarditis (RR, 3.82; 95% CI, 1.35-276 10.78), heart failure (RR, 1.77; 95% CI, 1.48-2.10), cardiomyopathy (RR, 1.78, 95% CI, 1.33-277 2.38), cardiac arrest (RR, 1.45; 95% CI, 1.06-1.98), thrombophlebitis (RR, 2.65; 95% CI, 1.18-278 5.96), thromboembolism (RR, 1.44; 95% CI, 1.14-1.81), chest pain (RR, 2.01; 95% CI, 1.64-279 2.46), and palpitations (RR, 2.14; 95% CI, 1.57-2.92). Non-CHD patients saw increased risks in 280 hypertension (RR, 1.47; 95% CI, 1.35-1.60), ventricular arrhythmias (RR, 1.49; 95% CI, 1.23-281 1.81), premature atrial or ventricular contractions (RR, 1.77; 95% CI 1.07-2.95), pericarditis (RR, 282 1.85; 95% CI, 1.22-2.81), myocarditis (RR, 3.66; 95% CI, 2.67-5.01), heart failure (RR, 1.76; 95% 283 CI, 1.24-2.48), cardiomyopathy (RR, 1.50; 95% CI, 1.19-1.90), cardiac arrest (RR, 1.56; 95% CI, 284 1.19-2.03), cardiogenic shock (RR, 3.15; 95% CI, 1.54-6.43), pulmonary embolism (RR, 1.61; 285 95% CI, 1.15-2.24), thromboembolism (RR, 1.30; 95% CI, 1.12-1.52), chest pain (RR, 1.84; 95% 286 CI, 1.75-1.92), palpitations (RR, 1.98; 95% CI, 1.83-2.16), and syncope (RR, 1.30; 95% CI, 287 1.21-1.40).

Figure 3 demonstrated that the risks of post-acute cardiovascular composite outcomes were evident across age groups, race/ethnicity, gender, obesity status, severity of acute COVID-19, and dominant virus variants.

291 Sensitivity Analysis

292 Negative control experiments (Section S3) indicated a slight systematic error, as shown by a 293 minor shift in point estimates with wider CIs. Analyses excluding patients solely based on PASC 294 (Section S4), those without prior cardiovascular history within the baseline period (Section S5), 295 those from the first COVID-19 wave (March to May 2020, Section S6), and those at site L 296 (Section S7), all gave similar results as in the primary analyses. Adolescents over 12 and 297 children aged 5 to 11 displayed higher risks of any cardiovascular outcomes compared to 298 children under 5 (Section S8). NHW patients exhibited the highest risks of any cardiovascular 299 outcome, followed by Hispanic and NHB groups (Section S9). Gender differences were noted: 300 females showed higher risks for hypertension, deep vein thrombosis, and cardiac arrest, whereas 301 males were more prone to premature atrial or ventricular contractions, pulmonary embolism, and 302 thrombophlebitis (Section S10). Obesity was associated with increased risks of ventricular 303 arrhythmias, premature atrial or ventricular contractions, cardiogenic shock, pulmonary 304 embolism, and thrombophlebitis, but lower risks of cardiovascular-related symptoms (Section 305 S11). Patients with severe COVID-19 during the acute phase had higher risks across all 306 composite cardiovascular outcomes compared to the non-severe group (Section S12). The pre-307 Delta period saw the highest risk of any cardiovascular outcome, with consistent risks observed 308 across all dominant virus variants (Section S13).

309 Discussion

Our study involved 297,920 children and adolescents with COVID-19 and 915,402 without COVID-19. We found that those infected with SARS-CoV-2 exhibited increased risks for a range of post-acute cardiovascular outcomes, with RR between 1.26 and 2.92. These outcomes included hypertension, ventricular arrhythmias, myocarditis, heart failure, cardiomyopathy, cardiogenic shock, thromboembolism, chest pain, and palpitations, compared to non-infected 315 controls. These findings applied to patients both with and without CHDs, although children with 316 CHD showed a notably higher risk of atrial fibrillation. Especially noteworthy was the increased 317 risk of myocarditis in both groups consistent with prior studies showing an increased occurrence 318 of myocarditis in the months following the diagnosis of COVID-19, across different ages and genders ^{3,39–43}. Risks were consistently observed regardless of age, gender, race/ethnicity, obesity 319 320 status, severity of acute COVID-19, or virus variant. Even children and adolescents without a 321 history of any cardiovascular outcomes before SARS-CoV-2 infection showed increased risks, 322 suggesting a broad potential impact on those previously considered at low risk of cardiovascular 323 disease. Our results were robust through extensive sensitivity analyses and negative control 324 experiments.

325 Our study has several strengths. First, we used the RECOVER EHR database to build a large cohort with and without COVID exposure, providing longitudinal follow-up throughout the post-326 327 acute period, which extended past findings in both populations and outcomes definitions. Second, 328 propensity score stratification, accommodating hundreds of covariates while balancing the 329 covariates in the two comparative groups, improved confounder adjustment over traditional linear regression, and reduced non-linear confounder effects⁴⁴. Third, all analyses were stratified 330 331 by CHD status, a unique consideration in the pediatric setting. We also employed RR as our comparative measure, important for its collapsibility³⁴ and accurate interpretation in clinical 332 research³³. Lastly, we conducted negative control experiments^{37,38} to address systematic bias and 333 334 control unmeasured confounders.

The COVID-19 pandemic prompted the widespread use of social distancing, masking,
subsequently vaccines, and medications. As acute cases declined, attention shifted towards longterm sequelae like cardiovascular PASC, particularly significant in pediatric patients, including

competitive athletes with a history of COVID-19 and any subsequent cardiac complications^{45,46}.
The substantial risks of post-acute cardiovascular effects of SARS-CoV-2 in pediatrics call for
dedicated healthcare resource allocation and long-term monitoring focused on cardiovascular
health.

342 Limitations

343 This study has several limitations. First, selecting high-quality COVID-19 controls is challenging due to potential misclassification⁴⁷; to mitigate this, we incorporated a combination of PCR, 344 345 antigen, and serology tests, along with diagnosis codes for COVID-19 and long COVID, to 346 define our COVID-19 control group more accurately. On the other hand, although historical or 347 pre-pandemic controls have been suggested, this introduces distinct difficulties for pediatric 348 research due to the dynamic nature of rapid physical growth and physiological, cognitive, 349 emotional, and social development in children and adolescents, which may not align with pre-350 pandemic benchmarks and could potentially lead to misleading results. Therefore, we used 351 contemporary controls in our primary analyses for a valid comparison. In addition, the increased 352 use of at-home rapid antigen tests later in the pandemic may have resulted in underreported 353 testing frequencies in EHRs. Nonetheless, our sensitivity analyses across different pandemic phases were consistent, showing resilience to the influence of viral variants and mitigating 354 355 concerns about data capture completeness.

Second, observational studies inherently face the challenge of confounding bias. To mitigate this, we used a propensity-score-based stratification approach and included a large number of potential confounders. We also incorporated the negative control experiments^{37,38} in our sensitivity analyses to adjust for unmeasured confounders. However, EHR data may still suffer from misclassification biases, such as incorrect documentation of SARS-CoV-2 infection status
 or incomplete follow-up data. Some efforts to lessen these biases have been made.^{37,38,48,49}

Third, the frequency of hospital visits⁵⁰ by COVID-19-positive patients might bias the observed post-acute cardiovascular outcomes upward, as these patients may visit hospitals more frequently. We tried to address this by including healthcare utilization factors such as hospital visits and tests as confounders to balance the comparison groups.

Fourth, our analysis did not account for reinfection or COVID-19 vaccinations during the study period, which could affect outcomes like myocarditis or pericarditis.^{13,51–53} We included the dosage of COVID-19 vaccines and the interval since the last immunization as confounders to partially adjust for these variables, but vaccinations and tests conducted outside hospital systems may not be captured accurately in the EHR.

Lastly, cardiovascular diagnoses were based on ICD or SNONED codes without chart review
confirmation, which can lead to misclassification. Also, the absence of family history data in our
EHR limits understanding of the predisposition of patients to cardiovascular conditions due to
familial trends.

In summary, this study shows a heightened risk of cardiovascular disease in children following
SARS-CoV-2 infection, with similar risks observed in those with and without pre-existing
congenital heart disease. Awareness of cardiovascular complications in the post-acute phase will
improve timely diagnosis and treatment of these conditions.

379 Acknowledgments

- This study is part of the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative,
 which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection
 (PASC). For more information on RECOVER, visit https://recovercovid.org/.
- We would like to thank the National Community Engagement Group (NCEG), all patients, caregivers, and community Representatives, and all the participants enrolled in the RECOVER Initiative. We would like to thank the patient representatives Megan Carmilani, Nick Guthe, and Leah Baucom for their helpful suggestions and comments.

387 Source of Funding

This work was supported in part by National Institutes of Health (OT2HL161847-01, 388 389 1R01LM014344, 1R01AG077820, R01LM012607, R01AI130460, R01AG073435, 390 R56AG074604, R01LM013519, R56AG069880, U01TR003709, RF1AG077820, R21AI167418, 391 R21EY034179). This work was supported partially through Patient-Centered Outcomes 392 Research Institute (PCORI) Project Program Awards (ME-2019C3-18315 and ME-2018C3-14899). All statements in this report, including its findings and conclusions, are solely those of 393 394 the authors and do not necessarily represent the views of the Patient-Centered Outcomes 395 Research Institute (PCORI), its Board of Governors or Methodology Committee.

396 **Disclosures**

- 397 This content is solely the responsibility of the authors and does not necessarily represent the398 official views of the RECOVER Initiative, the NIH, or other funders.
- 399 All authors have no conflicts of interest to report.

400 Supplemental Material

- 401 Protocol and Statistical Analysis Plan
- 402 Supplemental Methods/Dataset/Tables S1-S3/Figures S1_S15

403 **References**

- 1. Toepfner N, Brinkmann F, Augustin S, Stojanov S, Behrends U. Long COVID in
- 405 pediatrics—epidemiology, diagnosis, and management. *Eur J Pediatr*. Published online
 406 2024.
- 407 2. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of
 408 COVID-19. *Nature*. 2021;594(7862):259-264.
- 409 3. Rao S, Lee GM, Razzaghi H, et al. Clinical features and burden of postacute sequelae of
 410 SARS-CoV-2 infection in children and adolescents. *JAMA Pediatr.* 2022;176(10):1000-
- 411 1009.
- 412 4. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat*413 *Med.* 2022;28(3):583-590.
- 414 5. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to
 415 hospital with covid-19: retrospective cohort study. *bmj*. 2021;372.
- 416 6. Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of
 417 SARS-CoV-2 infection: retrospective cohort study. *Bmj.* 2021;373.
- 418 7. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.
 419 *JAMA*. 2020;324(6):603-605.
- 420 8. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
- discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-232.
- 422 9. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of
- 423 COVID-19 with a cardiovascular focus. *Eur Heart J*. 2022;43(11):1157-1172.
- 424 10. Wang W, Wang CY, Wang SI, Wei JCC. Long-term cardiovascular outcomes in COVID-
- 425 19 survivors among non-vaccinated population: a retrospective cohort study from the
- 426 TriNetX US collaborative networks. *EClinicalMedicine*. 2022;53.

- 427 11. Lim JT, Liang En W, Tay AT, et al. Long-term Cardiovascular, Cerebrovascular, and
- 428 Other Thrombotic Complications in COVID-19 Survivors: A Retrospective Cohort Study.
 429 *Clinical Infectious Diseases*. 2024;78(1):70-79.
- 430 12. Rao S, Gross RS, Mohandas S, et al. Postacute Sequelae of SARS-CoV-2 in Children.
 431 *Pediatrics*. Published online 2024:e2023062570.
- 432 13. Block JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2
 433 infection and mRNA COVID-19 vaccination—PCORnet, United States, january 2021–
 434 January 2022. *Morbidity and Mortality Weekly Report*. 2022;71(14):517.
- 435 14. Abi Nassif T, Fakhri G, Younis NK, et al. Cardiac manifestations in COVID-19 patients: a
- focus on the pediatric population. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2021;2021.
- 438 15. Chakraborty A, Johnson JN, Spagnoli J, et al. Long-term cardiovascular outcomes of
 439 multisystem inflammatory syndrome in children associated with COVID-19 using an
 440 institution based algorithm. *Pediatr Cardiol.* 2023;44(2):367-380.
- 441 16. Wu Q, Tong J, Zhang B, et al. Real-World Effectiveness of BNT162b2 Against Infection
 442 and Severe Diseases in Children and Adolescents. *Ann Intern Med.* Published online
 443 2024.
- Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the
 cardiovascular system. *Circulation*. 2020;142(1):68-78.
- 446 18. Bozkurt B, Das SR, Addison D, et al. 2022 AHA/ACC key data elements and definitions
- for cardiovascular and noncardiovascular complications of COVID-19: a report of the
- American College of Cardiology/American Heart Association Task Force on Clinical Data
 Standards. *Circ Cardiovasc Qual Outcomes*. 2022;15(7):e000111.
- 450 19. Van Der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJM. The
 451 changing epidemiology of congenital heart disease. *Nat Rev Cardiol.* 2011;8(1):50-60.

- 452 20. Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic
 453 dialysis patients. *Kidney Int*. 2002;62(2):648-653.
- 454 21. Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children
 455 and Kawasaki disease: a critical comparison. *Nat Rev Rheumatol.* 2021;17(12):731-748.
- 456 22. Harahsheh AS, Shah S, Dallaire F, et al. Kawasaki Disease in the Time of COVID-19 and
- 457 MIS-C: The International Kawasaki Disease Registry. *Canadian Journal of Cardiology*.
 458 2024;40(1):58-72.
- 459 23. Peco-Antić A, Paripović D. Renal hypertension and cardiovascular disorder in children
 460 with chronic kidney disease. *Srp Arh Celok Lek*. 2014;142(1-2):113-117.
- 461 24. Weaver DJ, Mitsnefes M. Cardiovascular disease in children and adolescents with
- 462 chronic kidney disease. In: *Seminars in Nephrology*. Vol 38. Elsevier; 2018:559-569.
- 463 25. Pawar SM. Multi system inflammatory syndrome in children and adolescents temporally
 464 related to COVID-19. *GFNPSS-Int J Multidiscip Res.* 2020;1(3):97-102.
- 465 26. Matsubara D, Kauffman HL, Wang Y, et al. Echocardiographic findings in pediatric
- 466 multisystem inflammatory syndrome associated with COVID-19 in the United States. J
- 467 *Am Coll Cardiol*. 2020;76(17):1947-1961.
- 468 27. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S.
- 469 Department of Health and Human Services, CDC. Published December 15, 2023.
- 470 https://covid.cdc.gov/covid-data-tracker
- 471 28. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative
- 472 effectiveness and safety of first-line antihypertensive drug classes: a systematic,
- 473 multinational, large-scale analysis. *The Lancet*. 2019;394(10211):1816-1826.
- 474 29. Simon TD, Haaland W, Hawley K, Lambka K, Mangione-Smith R. Development and
- 475 validation of the Pediatric Medical Complexity Algorithm (PMCA) version 3.0. *Acad*
- 476 *Pediatr.* 2018;18(5):577-580.

- Woodruff RC, Campbell AP, Taylor CA, et al. Risk factors for severe COVID-19 in
 children. *Pediatrics*. 2022;149(1):e2021053418.
- 479 31. Walker AM, Patrick AR, Lauer MS, et al. A tool for assessing the feasibility of
- 480 comparative effectiveness research. *Comparative effectiveness research*. Published481 online 2013:11-20.
- 482 32. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates
 483 between treatment groups in propensity-score matched samples. *Stat Med.*484 2009;28(25):3083-3107.
- 404 2009,20(25).3063-3107.
- 485 33. Whitcomb BW, Naimi AI. Defining, quantifying, and interpreting "noncollapsibility" in

486 epidemiologic studies of measures of "effect." *Am J Epidemiol*. 2021;190(5):697-700.

- 487 34. Greenland S, Pearl J, Robins JM. Confounding and collapsibility in causal inference.
 488 Statistical science. 1999;14(1):29-46.
- 489 35. Forrest CB, Burrows EK, Mejias A, et al. Severity of acute COVID-19 in children< 18
 490 years old March 2020 to December 2021. *Pediatrics*. 2022;149(4):e2021055765.
- 491 36. GISAID, via CoVariants.org Last updated 26 February 2024 processed by Our World
- 492 in Data. https://ourworldindata.org/grapher/covid-variants-area?time=earliest..2023-03493 06&country=~USA
- 494 37. Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence
- 495 interval calibration for population-level effect estimation studies in observational
- 496 healthcare data. *Proceedings of the National Academy of Sciences*. 2018;115(11):2571-
- 497 2577.
- 498 38. Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting
- 499 observational studies: why empirical calibration is needed to correct p-values. *Stat Med*.
- 500 2014;33(2):209-218.
- 39. Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of
 SARS-CoV-2 infection: retrospective cohort study. *bmj*. 2021;373.

- Murk W, Gierada M, Fralick M, Weckstein A, Klesh R, Rassen JA. Diagnosis-wide
 analysis of COVID-19 complications: an exposure-crossover study. *Cmaj.*2021;193(1):E10-E18.
- 506 41. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and
 507 myocarditis using hospital-based administrative data—United States, March 2020–
 508 January 2021. *Morbidity and Mortality Weekly Report*. 2021;70(35):1228.
- 509 42. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19
 510 vaccine in a nationwide setting. *New England Journal of Medicine*. 2021;385(12):1078511 1090.
- 43. Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with Covid-19 disease: a
 systematic review of published case reports and case series. *Int J Clin Pract.*

514 2021;75(11):e14470.

515 44. Amoah J, Stuart EA, Cosgrove SE, et al. Comparing propensity score methods versus

516 traditional regression analysis for the evaluation of observational data: a case study

- 517 evaluating the treatment of gram-negative bloodstream infections. *Clinical Infectious*
- 518 *Diseases*. 2020;71(9):e497-e505.
- 519 45. Chowdhury D, Fremed MA, Dean P, et al. Return to activity after SARS-CoV-2 infection:
 520 cardiac clearance for children and adolescents. *Sports Health*. 2022;14(4):460-465.
- 521 46. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical
- 522 myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big
- 523 ten COVID-19 cardiac registry. *JAMA Cardiol*. 2021;6(9):1078-1087.
- 524 47. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms
 525 and recommendations. *Nat Rev Microbiol*. 2023;21(3):133-146.
- 526 48. Chen Y, Wang J, Chubak J, Hubbard RA. Inflation of type I error rates due to differential
- 527 misclassification in EHR-derived outcomes: empirical illustration using breast cancer
- 528 recurrence. *Pharmacoepidemiol Drug Saf.* 2019;28(2):264-268.

- 529 49. Duan R, Cao M, Wu Y, et al. An empirical study for impacts of measurement errors on
 530 EHR based association studies. In: *AMIA Annual Symposium Proceedings*. Vol 2016.
 531 American Medical Informatics Association; 2016:1764.
- 532 50. Asch DA, Sheils NE, Islam MN, Chen Y, Werner RM, Buresh J. Variation in US Hospital
 533 Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the
- 534 Pandemic. JAMA Intern Med. 2021; 181 (4): 471–8. Published online 2020.
- 535 51. Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related
- to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after
- 537 COVID-19 vaccination. *Circulation*. 2022;145(5):345-356.
- 538 52. Kohli U, Desai L, Chowdhury D, et al. mRNA coronavirus disease 2019 vaccine-
- associated myopericarditis in adolescents: a survey study. *J Pediatr*. 2022;243:208-213.
- 540 53. Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a
- 541 COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior
- 542 SARS-CoV-2 infection: A self-controlled case series analysis in England. *PLoS Med.*
- 543 2023;20(6):e1004245.
- 544
- 545

	COVID-19-positive			COVID-19-negative			
	CHD (N=13,646)	Non-CHD (N=284,274)	Overall (N=297,920)	CHD (N=46,962)	Non-CHD (N=868,440)	Overall (N=915,402)	
Age							
Median [Q1, Q3]	3.0 [1.0, 8.0]	8.0 [2.0, 14.0]	8.0 [2.0, 14.0]	3.0 [1.0, 8.0]	7.0 [2.0, 13.0]	6.0 [2.0, 13.0]	
Year of Age, no. (%	6)						
0	3,126 (22.9)	35,297 (12.4)	38,423 (12.9)	11,632 (24.8)	90,104 (10.4)	101,736 (11.1)	
1	1,879 (13.8)	22,792 (8.0)	24,671 (8.3)	5,486 (11.7)	80,038 (9.2)	85,524 (9.3)	
2	1,214 (8.9)	16,011 (5.6)	17,225 (5.8)	3,765 (8.0)	60,131 (6.9)	63,896 (7.0)	
3	1,007 (7.4)	13,679 (4.8)	14,686 (4.9)	3,547 (7.6)	54,274 (6.2)	57,821 (6.3)	
4	810 (5.9)	13,439 (4.7)	14,249 (4.8)	3,111 (6.6)	52,261 (6.0)	55,372 (6.0)	
5	725 (5.3)	12,248 (4.3)	12,973 (4.4)	2,856 (6.1)	50,846 (5.9)	53,702 (5.9)	
6	588 (4.3)	11,603 (4.1)	12,191 (4.1)	2,292 (4.9)	44,811 (5.2)	47,103 (5.1)	
7	491 (3.6)	11,270 (4.0)	11,761 (3.9)	1,839 (3.9)	39,620 (4.6)	41,459 (4.5)	
8	429 (3.1)	11,105 (3.9)	11,534 (3.9)	1,513 (3.2)	35,983 (4.1)	37,496 (4.1)	
9	410 (3.0)	11,229 (4.0)	11,639 (3.9)	1,358 (2.9)	33,960 (3.9)	35,318 (3.9)	
10	370 (2.7)	11,820 (4.2)	12,190 (4.1)	1,213 (2.6)	32,537 (3.7)	33,750 (3.7)	
11	374 (2.7)	12,532 (4.4)	12,906 (4.3)	1,174 (2.5)	32,381 (3.7)	33,555 (3.7)	
12	282 (2.1)	10,969 (3.9)	11,251 (3.8)	989 (2.1)	31,364 (3.6)	32,353 (3.5)	
13	276 (2.0)	11,583 (4.1)	11,859 (4.0)	993 (2.1)	32,054 (3.7)	33,047 (3.6)	
14	275 (2.0)	12,273 (4.3)	12,548 (4.2)	974 (2.1)	33,222 (3.8)	34,196 (3.7)	
15	277 (2.0)	13,051 (4.6)	13,328 (4.5)	962 (2.0)	33,911 (3.9)	34,873 (3.8)	
16	278 (2.0)	13,268 (4.7)	13,546 (4.5)	896 (1.9)	34,232 (3.9)	35,128 (3.8)	
17	275 (2.0)	13,181 (4.6)	13,456 (4.5)	825 (1.8)	33,998 (3.9)	34,823 (3.8)	
18	225 (1.6)	9,695 (3.4)	9,920 (3.3)	615 (1.3)	24,962 (2.9)	25,577 (2.8)	
19	160 (1.2)	8,725 (3.1)	8,885 (3.0)	480 (1.0)	19,826 (2.3)	20,306 (2.2)	
20	175 (1.3)	8,504 (3.0)	8,679 (2.9)	442 (0.9)	17,925 (2.1)	18,367 (2.0)	
Gender, no. (%)							
Female	6,333 (46.4)	141,868 (49.9)	148,201 (49.7)	22,066 (47.0)	419,249 (48.3)	441,315 (48.2)	
Male	7,313 (53.6)	142,406 (50.1)	149,719 (50.3)	24,896 (53.0)	449,191 (51.7)	474,087 (51.8)	
Race/Ethnicity, no.	. (%)						
NHW	6,247 (45.8)	118,054 (41.5)	124,301 (41.7)	23,067 (49.1)	395,378 (45.5)	418,445 (45.7)	
NHB	2,307 (16.9)	51,139 (18.0)	53,446 (17.9)	7,294 (15.5)	147,576 (17.0)	154,870 (16.9)	
Hispanic	3,197 (23.4)	70,834 (24.9)	74,031 (24.8)	9,662 (20.6)	187,025 (21.5)	196,687 (21.5)	
AAPI	586 (4.3)	13,573 (4.8)	14,159 (4.8)	2,124 (4.5)	41,659 (4.8)	43,783 (4.8)	
Multiple	400 (2.9)	7,493 (2.6)	7,893 (2.6)	1,486 (3.2)	26,357 (3.0)	27,843 (3.0)	
Other/Unknown	909 (6.7)	23,181 (8.2)	24,090 (8.1)	3,329 (7.1)	70,445 (8.1)	73,774 (8.1)	

Table 1. Baseline characteristics of patients, stratified by COVID-19 status and CHD status.

Health System, no. (%)								
А	1,212 (8.9)	26,724 (9.4)	27,936 (9.4)	4,259 (9.1)	86,746 (10.0)	91,005 (9.9)		
В	1,730 (12.7)	52,598 (18.5)	54,328 (18.2)	6,099 (13.0)	134,278 (15.5)	140,377 (15.3)		
С	1,251 (9.2)	13,977 (4.9)	15,228 (5.1)	4,890 (10.4)	61,282 (7.1)	66,172 (7.2)		
D	99 (0.7)	5,222 (1.8)	5,321 (1.8)	255 (0.5)	10,480 (1.2)	10,735 (1.2)		
Е	838 (6.1)	7,171 (2.5)	8,009 (2.7)	3,234 (6.9)	35,653 (4.1)	38,887 (4.2)		
F	702 (5.1)	12,351 (4.3)	13,053 (4.4)	2,806 (6.0)	47,709 (5.5)	50,515 (5.5)		
G	431 (3.2)	6,942 (2.4)	7,373 (2.5)	872 (1.9)	16,838 (1.9)	17,710 (1.9)		
Н	606 (4.4)	9,178 (3.2)	9,784 (3.3)	1,816 (3.9)	28,694 (3.3)	30,510 (3.3)		
I	344 (2.5)	5,121 (1.8)	5,465 (1.8)	1,041 (2.2)	13,666 (1.6)	14,707 (1.6)		
J	1,165 (8.5)	22,316 (7.9)	23,481 (7.9)	4,845 (10.3)	102,912 (11.9)	107,757 (11.8)		
К	1,154 (8.5)	23,754 (8.4)	24,908 (8.4)	4,048 (8.6)	85,730 (9.9)	89,778 (9.8)		
L	593 (4.3)	55,135 (19.4)	55,728 (18.7)	1,180 (2.5)	116,396 (13.4)	117,576 (12.8)		
М	539 (3.9)	8,408 (3.0)	8,947 (3.0)	1,259 (2.7)	14,638 (1.7)	15,897 (1.7)		
0	8 (0.1)	673 (0.2)	681 (0.2)	27 (0.1)	1,693 (0.2)	1,720 (0.2)		
Р	593 (4.3)	4,143 (1.5)	4,736 (1.6)	2,359 (5.0)	24,422 (2.8)	26,781 (2.9)		
Q	502 (3.7)	7,947 (2.8)	8,449 (2.8)	2,069 (4.4)	24,457 (2.8)	26,526 (2.9)		
R	10 (0.1)	10 (0.1) 402 (0.1) 412		7 (0.0)	317 (0.0)	324 (0.0)		
S	798 (5.8)	798 (5.8) 10,723 (3.8) 11,521		2,638 (5.6)	34,231 (3.9)	36,869 (4.0)		
Т	1,071 (7.8)	11,489 (4.0)	12,560 (4.2)	3,258 (6.9)	28,298 (3.3)	31,556 (3.4)		
Entry time, no. (%)								
03/2020 - 05/2020	167 (1.2)	2,708 (1.0)	2,875 (1.0)	1,545 (3.3)	15,812 (1.8)	17,357 (1.9)		
06/2020 - 08/2020	308 (2.3)	9,681 (3.4)	9,989 (3.4)	4,028 (8.6)	56,525 (6.5)	60,553 (6.6)		
09/2020 - 11/2020	588 (4.3)	16,600 (5.8)	17,188 (5.8)	4,305 (9.2)	78,031 (9.0)	82,336 (9.0)		
12/2020 - 02/2021	1,025 (7.5)	28,124 (9.9)	29,149 (9.8)	3,761 (8.0)	75,910 (8.7)	79,671 (8.7)		
03/2021 - 05/2021	729 (5.3)	16,304 (5.7)	17,033 (5.7)	4,316 (9.2)	79,840 (9.2)	84,156 (9.2)		
06/2021 - 08/2021	726 (5.3)	16,924 (6.0)	17,650 (5.9)	4,466 (9.5)	78,411 (9.0)	82,877 (9.1)		
09/2021 - 11/2021	1,140 (8.4)	26,733 (9.4)	27,873 (9.4)	5,259 (11.2)	120,200 (13.8)	125,459 (13.7)		
12/2021 - 02/2022	3,736 (27.4)	82,586 (29.1)	86,322 (29.0)	4,243 (9.0)	89,917 (10.4)	94,160 (10.3)		
03/2022 - 05/2022	1,188 (8.7)	20,014 (7.0)	21,202 (7.1)	3,770 (8.0)	67,148 (7.7)	70,918 (7.7)		
06/2022 - 08/2022	1,889 (13.8)	32,369 (11.4)	34,258 (11.5)	3,172 (6.8)	52,367 (6.0)	55,539 (6.1)		
09/2022 - 11/2022	956 (7.0)	15,140 (5.3)	16,096 (5.4)	4,291 (9.1)	83,680 (9.6)	87,971 (9.6)		
12/2022 – 03/2023	1,194 (8.7)	17,091 (6.0)	18,285 (6.1)	3,806 (8.1)	70,599 (8.1)	74,405 (8.1)		
Obesity, no. (%)								

No	8,861 (64.9)	149,365 (52.5)	158,226 (53.1)	31,985 (68.1)	495,600 (57.1)	527,585 (57.6)		
Yes	Yes 4,425 (32.4) 110,		115,308 (38.7)	13,057 (27.8)	288,267 (33.2)	301,324 (32.9)		
Unknown	360 (2.6)	24,026 (8.5)	24,386 (8.2)	1,920 (4.1)	84,573 (9.7)	86,493 (9.4)		
PMCA, no. (%)								
0	3,172 (23.2)	202,897 (71.4)	206,069 (69.2)	12,383 (26.4)	619,127 (71.3)	631,510 (69.0)		
1	2,544 (18.6)	48,078 (16.9)	50,622 (17.0)	8,759 (18.7)	146,594 (16.9)	155,353 (17.0)		
2	7,930 (58.1)	33,299 (11.7)	41,229 (13.8)	25,820 (55.0)	102,719 (11.8)	128,539 (14.0)		
Number of negativ	ve COVID-19 tests be	fore index date, no. (%	(0)					
0	5,633 (41.3)	169,814 (59.7)	175,447 (58.9)	29,732 (63.3)	649,004 (74.7)	678,736 (74.1)		
1	2,855 (20.9)	60,909 (21.4)	63,764 (21.4)	8,764 (18.7)	141,107 (16.2)	149,871 (16.4)		
2	1,605 (11.8)	25,685 (9.0)	27,290 (9.2)	3,637 (7.7)	44,266 (5.1)	47,903 (5.2)		
≥3	3,553 (26.0)	27,866 (9.8)	31,419 (10.5)	4,829 (10.3)	34,063 (3.9)	38,892 (4.2)		
Dosage of COVID	-19 vaccine, no. (%)							
0	9,995 (73.2)	175,674 (61.8)	185,669 (62.3)	34,796 (74.1)	566,168 (65.2)	600,964 (65.7)		
1	773 (5.7)	17,218 (6.1)	17,991 (6.0)	2,336 (5.0)	46,143 (5.3)	48,479 (5.3)		
≥2	2,878 (21.1)	91,382 (32.1)	94,260 (31.6)	9,830 (20.9)	256,129 (29.5)	265,959 (29.1)		
Number of unique medications, no. (%)								
0	1,458 (10.7)	61,432 (21.6)	62,890 (21.1)	7,221 (15.4)	224,089 (25.8)	231,310 (25.3)		
1	768 (5.6)	31,344 (11.0)	32,112 (10.8)	3,397 (7.2)	100,046 (11.5)	103,443 (11.3)		
2	646 (4.7)	26,711 (9.4)	27,357 (9.2)	2,580 (5.5)	80,440 (9.3)	83,020 (9.1)		
≥3	10,774 (79.0)	164,787 (58.0)	175,561 (58.9)	33,764 (71.9)	463,865 (53.4)	497,629 (54.4)		

548 Table 2. Absolute risks (in %, incident/total patients) of individual and composite cardiovascular

549 outcomes, stratified by COVID-19 status and CHD status.

550	COVID-19-positive		COVID-19-negative			
	CHD (N=13,646)	Non-CHD (N=284,274)	Overall (N=297,920)	CHD (N=46,962)	Non-CHD (N=868,440)	Overall (N=915,402)
Any cardiovascular outcome	5.566 (601/10797)	2.19 (5895/269210)	2.32 (6496/280007)	3.998 (1529/38248)	1.261 (10481/831098)	1.381 (12010/869346)
Hypertension	1.531 (195/12736)	0.333 (936/281427)	0.384 (1131/294163)	1.08 (481/44548)	0.209 (1801/861469)	0.252 (2282/906017)
Any arrhythmias	0.967 (126/13029)	$\begin{array}{c} 0.073\\(208/283655)\end{array}$	0.113 (334/296684)	0.79 (355/44955)	$\begin{array}{c} 0.053 \\ (461/866011) \end{array}$	0.09 (816/910966)
Atrial fibrillation	0.081 (11/13619)	0.006 (16/284233)	0.009 (27/297852)	0.038 (18/46896)	0.005 (46/868329)	0.007 (64/915225)
Ventricular arrhythmias	0.863 (113/13089)	0.06 (171/283757)	0.096 (284/296846)	0.695 (314/45159)	0.044 (378/866270)	0.076 (692/911429)
Atrial flutter	0.059 (8/13577)	0.002 (7/284243)	0.005 (15/297820)	0.092 (43/46754)	0.002 (17/868365)	0.007 (60/915119)
Premature atrial or ventricular contractions	0.059 (8/13619)	0.009 (26/284206)	0.011 (34/297825)	0.058 (27/46862)	0.006 (52/868245)	0.009 (79/915107)
Any inflammatory heart disease	0.125 (17/13603)	0.044 (126/284132)	0.048 (143/297735)	0.094 (44/46828)	0.015 (134/868141)	0.019 (178/914969)
Pericarditis	0.081 (11/13628)	0.014 (39/284198)	0.017 (50/297826)	0.077 (36/46886)	0.007 (64/868296)	0.011 (100/915182)
Myocarditis	0.059 (8/13620)	0.034 (97/284185)	0.035 (105/297805)	0.019 (9/46902)	0.01 (83/868259)	0.01 (92/915161)
Any other cardiac disorders	2.236 (281/12565)	0.079 (225/283615)	0.171 (506/296180)	1.632 (710/43513)	0.055 (474/866289)	0.13 (1184/909802)
Heart failure	1.609 (208/12930)	0.02 (57/284114)	0.089 (265/297044)	1.179 (527/44688)	0.012 (106/868010)	0.069 (633/912698)
Cardiomyopathy	0.578 (77/13331)	$0.042 \\ (118/283824)$	0.066 (195/297155)	0.361 (166/46046)	0.028 (245/867069)	0.045 (411/913115)
Cardiac arrest	0.483 (65/13461)	0.032 (91/284122)	0.052 (156/297583)	0.356 (165/46303)	0.022 (194/867807)	0.039 (359/914110)
Cardiogenic shock	0.155 (21/13526)	0.006 (17/284233)	0.013 (38/297759)	0.12 (56/46554)	0.002 (18/868332)	0.008 (74/914886)
Any thrombotic disorders	0.913 (119/13029)	0.102 (288/283427)	0.137 (407/296456)	0.737 (332/45039)	0.084 (728/865935)	$\begin{array}{c} 0.116 \\ (1060/910974) \end{array}$
Pulmonary embolism	0.103 (14/13618)	0.022 (62/284178)	0.026 (76/297796)	0.047 (22/46872)	$\begin{array}{c} 0.013\\(110/868175)\end{array}$	0.014 (132/915047)
Deep vein thrombosis	0.096 (13/13585)	0.011 (31/284188)	0.015 (44/297773)	0.062 (29/46848)	0.01 (86/868264)	0.013 (115/915112)
Thrombophlebitis	0.096 (13/13591)	0.018 (51/284141)	0.021 (64/297732)	0.036 (17/46817)	0.017 (151/867965)	0.018 (168/914782)
Thromboembolism	0.896 (117/13064)	0.091 (258/283513)	0.126 (375/296577)	0.72 (325/45113)	0.074 (639/866229)	0.106 (964/911342)
Cardiovascular- related symptoms	2.002 (259/12938)	1.748 (4772/272941)	$1.76 \\ (5031/285879)$	1.028 (463/45035)	0.959 (8071/842021)	0.962 (8534/887056)
Chest pain	1.345 (177/13160)	1.229 (3401/276688)	1.234 (3578/289848)	0.637 (292/45810)	0.611 (5202/851857)	0.612 (5494/897667)
Palpitations	0.564 (76/13474)	$0.378 \\ (1067/282181)$	0.387 (1143/295655)	0.274 (127/46402)	0.181 (1566/863436)	0.186 (1693/909838)
Syncope	0.371 (50/13482)	0.42 (1181/281122)	0.418 (1231/294604)	0.271 (126/46454)	0.298 (2563/860375)	0.297 (2689/906829)

551 Figure 1. Selection of participants for both COVID-19-positive and COVID-19-negative

552 patients, stratified by CHD status.



554 Figure 2. Relative Risk (RR) of incident post-acute COVID-19 cardiovascular outcomes 555 compared with the COVID-19-negative cohort, stratified by CHD status. Composite outcomes 556 consisted of arrhythmias (atrial fibrillation, ventricular arrhythmias, atrial flutter, and premature 557 atrial or ventricular contractions), inflammatory heart disease (pericarditis and myocarditis), 558 other cardiac disorders (heart failure, cardiomyopathy, cardiac arrest, and cardiogenic shock), 559 thrombotic disorders (pulmonary embolism, deep vein thrombosis, thrombophlebitis, and 560 thromboembolism), cardiovascular-related symptoms (chest pain, palpitations, and syncope), and 561 any cardiovascular outcome (incident occurrence of any cardiovascular outcome studied).

	Outcome Name	CHD	RR (95% CI)	non-CHD	RR (95% CI)
Hypertension	Hypertension		1.58 (1.32 to 1.89)	-	1.47 (1.35 to 1.60)
	Atrial fibrillation		→ 2.64 (1.15 to 6.05)	-	1.02 (0.56 to 1.86)
Annhuithneine	Ventricular arrhythmias		1.50 (1.18 to 1.89)		1.49 (1.23 to 1.81)
Arrnythmias	Atrial flutter		0.93 (0.42 to 2.07)		1.52 (0.59 to 3.90)
	Premature atrial or ventricular contractions		- 1.36 (0.58 to 3.21)		1.77 (1.07 to 2.95)
Inflammatory	Pericarditis		1.29 (0.62 to 2.69)		1.85 (1.22 to 2.81)
heart disease	Myocarditis		→ 3.82 (1.35 to 10.78)		→ 3.66 (2.67 to 5.01)
	Heart failure		1.77 (1.48 to 2.10)	·	- 1.76 (1.24 to 2.48)
Other cardiac	Cardiomyopathy		1.78 (1.33 to 2.38)		1.50 (1.19 to 1.90)
disorders	Cardiac arrest		1.45 (1.06 to 1.98)		1.56 (1.19 to 2.03)
	Cardiogenic shock		1.39 (0.80 to 2.42)		→ 3.15 (1.54 to 6.43)
	Pulmonary embolism		2.02 (0.96 to 4.22)		1.61 (1.15 to 2.24)
Thrombotic	Deep vein thrombosis		- 1.61 (0.79 to 3.28)	_ _	1.04 (0.67 to 1.60)
disorders	Thrombophlebitis		→ 2.65 (1.18 to 5.96)	- -	1.06 (0.76 to 1.49)
	Thromboembolism		1.44 (1.14 to 1.81)		1.30 (1.12 to 1.52)
Cardiovascular-	Chest pain		2.01 (1.64 to 2.46)	•	1.84 (1.75 to 1.92)
related	Palpitations		2.14 (1.57 to 2.92)		1.98 (1.83 to 2.16)
symptoms	Syncope	<u> </u>	1.39 (0.98 to 1.98)	+	1.30 (1.21 to 1.40)
		0.5 1 2	4	0.5 1 2	4
	Any cardiovascular outcome	+	1.63 (1.47 to 1.80)	•	1.63 (1.57 to 1.69)
	Any arrhythmias		1.52 (1.22 to 1.89)		1.47 (1.24 to 1.75)
Composite	Any inflammatory heart disease		1.65 (0.89 to 3.04)		2.92 (2.25 to 3.78)
outcomes	Any other cardiac disorders		1.69 (1.46 to 1.96)		1.50 (1.26 to 1.78)
	Any thrombotic disorders		1.42 (1.13 to 1.78)		1.26 (1.09 to 1.45)
	Any cardiovascular-related symptoms		1.95 (1.66 to 2.31)	•	1.68 (1.62 to 1.75)
		1 1 2	4	051 2	4
	0		7	0.01 2	7

Figure 3. Subgroup analyses of Relative Risk (RR) of incident post-acute COVID-19 composite
cardiovascular outcomes compared with the COVID-19-negative cohort, according to CHD
status, age, race/ethnicity, sex, obesity, severity during the acute phase of COVID-19, and the
dominant variant.

	1	Any cardiovascular outcome	Arrhythmias	Inflammatory heart disease	Other cardiac disorders	Thrombotic disorders	Cardiovascular-related symptoms
CHD	Yes	-	¦-∎			- -	
СПО	No						
	0 to 4	+		i	-=-	-	-=-
Age (years)	5 to 11	•			 -		•
	12 to 20	•			j - - -	H a -	•
	NHW			_	 -		
Race/Ethnicity	Hispanic	-	⊢ ∎—	\rightarrow	i- - -		•
	NHB	-			_ _		-
Sev	Male	-			i -	-=-	•
JEX	Female	•	-	\rightarrow		¦∎-	•
Obesity	Yes	-					•
Obesity	No		¦∎-	·	-	- =-	-
Soverity	Severe	-	¦ _∎		¦	- - -	
Sevency	Non-severe				¦ -∎-		
	pre-Delta		¦		¦-∎	┟╼╌	-
Virus	Delta	-	┼━──	¦ —	¦	¦ _∎	•
	Omicron	-			¦ -=-	¦∎-	-
		0.51 2 3	0.51 2 3	0.51 2 4.5	5 0.51 2 3	0.51 2 3	0.51 2 3
				RR (95% CI	1)		